



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry: 325682 MenQuadfi meningococcal (Groups A,C,Y,W) polysaccharide tetanus toxoid conjugate vaccine, solution for injection, vial

ARTG entry for Medicine Registered
Sponsor Sanofi-Aventis Australia Pty Ltd
Postal Address Locked Bag 2227, NORTH RYDE BC, NSW, 1670
 Australia
ARTG Start Date 29/10/2020
Product Category Medicine
Status Active
Approval Area Drug Safety Evaluation Branch



Medicine under additional monitoring

Conditions

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Products

1 . MenQuadfi meningococcal (Groups A,C,Y,W) polysaccharide tetanus toxoid conjugate vaccine, solution for injection, vial

Product Type	Single Medicine Product	Effective Date	8/06/2021
---------------------	-------------------------	-----------------------	-----------

Permitted Indications

No Permitted Indications included on Record

Indication Requirements

No Indication Requirements included on Record

Standard Indications

No Standard Indications included on Record

Specific Indications

MenQuadfi is indicated for active immunisation for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y., The use of MenQuadfi should be in accordance with official recommendations.

Warnings

See Product Information and Consumer Medicine Information for this product

Additional Product information

This product is included in the Black Triangle Scheme

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Vial	Glass Type I Clear	36 Months	Store at 2 to 8 degrees Celsius	Neither child resistant closure nor restricted flow insert	Not recorded

Pack Size/Poison information

Pack Size	Poison Schedule
5 vials per pack	(S4) Prescription Only Medicine
1 vial per pack	(S4) Prescription Only Medicine

Components

1 . MenQuadfi meningococcal (Groups A,C,Y,W) polysaccharide tetanus toxoid conjugate vaccine, solution for injection, vial

Dosage Form Injection, solution
Route of Administration Intramuscular
Visual Identification Clear, sterile, preservative-free solution

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

Active Ingredients

Meningococcal polysaccharide group A	10 microgram
Meningococcal polysaccharide group C	10 microgram
Meningococcal polysaccharide group W135	10 microgram
Meningococcal polysaccharide Group Y	10 microgram

Other Ingredients (Excipients)

sodium acetate
sodium chloride
Tetanus toxoid
water for injections

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary